Bay Street News

Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

August 26, 2019
- NASDAQ Companies
  0
ShareTweet
ShareTweet
» View More News for August 26, 2019

Tweets by baystnews

© 2020 BayStNews.com - All Rights Reserved
  • Home
  • TSX News
  • TSX Venture News
  • NASDAQ Companies
  • NYSE Companies
  • Canadian Stock Exchange News
  • Pink Sheets News
  • OTCBB News
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search